BPC-157

BPC-157 (10mg) — Pentadecapeptide Tissue-Repair Research Compound

BPC-157 (10mg) is supplied in Australia by Omega Peptides Australia from domestic stock, with same-day dispatch on orders placed before 12pm and an independent certificate of analysis for every batch. Commonly written as BPC157, BPC 157, BCP-157, BCP157, BP157, PBC 157 or Body Protective Compound, it is one of the most extensively studied repair peptides in current research.

BPC-157 is a synthetic pentadecapeptide, a chain of fifteen amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) that corresponds to a partial sequence of a protective protein first isolated from human gastric juice. It was first described in the early 1990s by a research group in Zagreb and has since become one of the most extensively studied repair peptides in preclinical science. The name stands for Body Protection Compound, and it is often written as BPC 157, BPC157, bcp 157, bp 157 or pbc 157, and sometimes referred to as pentadecapeptide BPC 157 or by its development code PL 14736.

BPC-157 is studied primarily in three directions: connective-tissue repair (tendon, ligament and muscle models), gastrointestinal protection (ulcer, fistula and colitis models) and vascular or neuroprotective effects. At the pathway level it is thought to act through the nitric-oxide system and growth-factor signalling, activating VEGFR2 and the FAK-paxillin pathway in fibroblasts and endothelial cells, which promotes angiogenesis, cell migration and collagen deposition in injured tissue.

Omega Peptides Australia supplies BPC-157 as a high-purity (≥99% HPLC) COA-verified lyophilised powder in a sealed sterile 10mg vial. Orders placed before 12pm are dispatched the same day from within Australia, and the batch Certificate of Analysis for every lot is published in our COA library. Researchers looking to buy BPC-157 in Australia get verified purity, transparent documentation and domestic supply with no customs delays.

Key research areas

• Tendon and ligament repair Rodent models of transected Achilles tendon, medial collateral ligament injury and tendon-to-bone healing have been used to study BPC-157. The proposed mechanism involves increased fibroblast migration and outgrowth from tendon explants, mediated by FAK-paxillin signalling and upregulation of growth-hormone receptor expression in tendon fibroblasts.
• Muscle recovery BPC-157 has been investigated in crush injury, muscle transection and corticosteroid-impaired healing models. Researchers have measured functional recovery, muscle fibre regeneration and reduced fibrosis, with angiogenesis and modulation of the inflammatory response proposed as the underlying drivers.
• Gastrointestinal protection The peptide was originally studied as a gastroprotective agent. Preclinical work spans gastric and duodenal ulcer models, fistulas, anastomosis healing, NSAID-induced lesions and inflammatory bowel disease models, and an early-phase clinical programme examined it in inflammatory bowel disease. Its stability in gastric juice makes oral administration a common design in these studies.
• Angiogenesis and blood flow BPC-157 has been studied for its effect on new blood-vessel formation and on the recovery of blood flow after vessel occlusion in rodent models. The mechanism is linked to nitric-oxide synthase activity and VEGFR2 activation in endothelial cells, with reports of collateral vessel recruitment after ligation of major veins and arteries.
• Neuroprotection and nerve repair Preclinical research has examined BPC-157 in peripheral nerve transection, traumatic brain injury and spinal-cord compression models. It has also been studied for interactions with the dopamine and serotonin systems, including counteraction of neuroleptic-induced effects in rodents.
• Organ and cytoprotection A broader body of rodent work investigates BPC-157 as a cytoprotective agent in liver, heart, pancreas and kidney injury models, often framed around the concept of a gut-brain and gut-organ protective axis. Modulation of the NO system and of prostaglandin-related pathways is proposed to explain these effects.

BPC-157 in Australia

BPC-157 is not registered on the Australian Register of Therapeutic Goods, so it is not stocked by Chemist Warehouse, Priceline or other pharmacies. In Australia it is supplied as a research-grade lyophilised vial by domestic research suppliers. Omega Peptides Australia holds BPC-157 in stock within Australia and dispatches orders placed before 12pm the same business day on tracked domestic delivery, so material arrives in days rather than waiting on an international shipment and customs. Every batch is tested independently and its certificate is published in the COA library before the vial ships.

BPC-157 is also available in Australia as oral capsules for researchers studying the gastric and systemic route, and as a BPC-157 + TB-500 blend for combined tissue-repair designs. Searches for BPC 157 tablets or BPC 157 capsules in Australia refer to the same compound in oral form.

How BPC-157 works

BPC-157 does not act through a single well-defined receptor. Instead, in vitro and rodent studies point to a set of converging mechanisms. In endothelial cells it activates VEGFR2 and downstream Akt-eNOS signalling, increasing nitric-oxide production and driving angiogenesis. In fibroblasts it triggers the FAK-paxillin pathway, which increases cell migration and survival, and it upregulates the expression of early growth response genes (egr-1 and its co-repressor NAB2), which regulate cytokine and growth-factor production during wound healing. Together these effects are thought to explain the increased collagen deposition and faster tissue reorganisation reported in repair models.

What sets BPC-157 apart from related compounds is its stability. The peptide has been reported to remain intact in human gastric juice for more than 24 hours, which is unusual for a linear peptide and is the reason both oral and injectable formats appear in the research literature. Detailed pharmacokinetic data in humans are limited, so half-life is not reliably established. Compared with TB-500, which acts by binding actin to promote cell migration, BPC-157 works mainly through growth-factor and nitric-oxide signalling, which is why the two are frequently studied side by side and are also offered as a combined BPC-157 + TB-500 blend.

Specifications

Available sizes and pricing

BPC-157 is supplied in a single 10mg vial size. Each vial contains 10mg of lyophilised peptide with the batch number printed on the label, so the result can be matched to its Certificate of Analysis. For laboratories comparing formats, the same compound is also available as pre-measured oral BPC-157 capsules, and in a combined vial with TB-500.

• 10mg vial — $99.99 (about $10.00 per mg)

Quality and COA verification

Every batch of BPC-157 is independently tested by Janoshik Analytical, with HPLC used to confirm purity and mass spectrometry used to confirm the identity of the peptide against its expected molecular weight. A Certificate of Analysis is issued for every batch and published in our COA library, where the batch number on your vial can be checked against the report. The peptide is lyophilised for stability and sealed in a sterile vial under an inert environment, then packed in protective packaging for domestic transit. Because stock is held in Australia, vials are not exposed to extended international shipping or customs holds before they reach your laboratory.

Frequently bought together

• TB-500 (10mg) — $99.99, the actin-binding peptide most often studied alongside BPC-157 in repair models
• BPC-157 + TB-500 Blend (10mg) — $119.99, both compounds pre-combined in one vial for simpler preparation
• BPC-157 Capsules (100 caps) — $249.99, an oral 500mcg format for gastrointestinal research designs
• Bacteriostatic Water (10mL) — $29.99, for reconstituting the lyophilised powder

Research guides

• BPC-157 research guide
• Best place to buy BPC-157 in Australia
• BPC-157 vs TB-500
• GHK-Cu vs BPC-157
• How to store lyophilised peptides
• COA testing explained
• Peptide reconstitution calculator
• Certificates of Analysis library

Frequently asked questions

What is BPC?
BPC is the everyday shorthand for BPC-157, where the letters stand for Body Protection Compound. The number 157 identifies the specific fifteen-amino-acid fragment that was isolated and synthesised from a larger gastric protein. When researchers, forums or search queries refer to BPC, BPC 157 or BPC157, they almost always mean this same pentadecapeptide, which is supplied here as a 10mg lyophilised research compound.

What is BPC-157?
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, derived from a protein found in human gastric juice. It has been investigated in preclinical models for over three decades, most notably in tendon, ligament, muscle and gastrointestinal injury models. It is a cytoprotective research compound rather than a hormone, and it is notable for remaining stable in gastric juice for more than 24 hours.

What is BPC-157 also known as?
It is also written as BPC 157, BPC157 and bpc-157 peptide, and commonly misspelled as bcp 157, bcp157, bp 157, bp157, pbc 157, boc 157 or peptide 157. Formal names include Body Protection Compound-157 and pentadecapeptide BPC 157, and the development code PL 14736 appears in early clinical literature. In online discussion it is sometimes nicknamed the healing peptide because of the breadth of repair models in which it has been studied.

How does BPC-157 work?
In vitro and rodent studies suggest BPC-157 acts through several converging pathways rather than a single receptor. It activates VEGFR2 and nitric-oxide signalling in endothelial cells, which promotes angiogenesis, and it stimulates the FAK-paxillin pathway in fibroblasts, increasing cell migration and collagen production. It also modulates early growth response genes involved in cytokine regulation and interacts with the dopamine and serotonin systems in neurological models.

What does the research show about BPC-157?
Preclinical studies in rodents have reported faster structural and functional recovery in tendon, ligament, muscle and nerve injury models, protection of the gastric and intestinal lining against ulceration and NSAID damage, improved healing of fistulas and anastomoses, and recovery of blood flow after vessel occlusion. Human data remain limited to a small number of early-phase clinical studies in inflammatory bowel disease, so the compound is still classed as investigational.

Can I buy BPC-157 at Chemist Warehouse or a pharmacy in Australia?
No. There is no BPC-157 product registered on the Australian Register of Therapeutic Goods, so Chemist Warehouse, Priceline and other retail pharmacies do not stock it. The research-grade lyophilised peptide supplied here is a laboratory reagent, not a pharmacy medicine.

Can Australian compounding pharmacies supply BPC-157?
Compounding pharmacies in Australia prepare medicines only for an individual patient on a practitioner's prescription and do not sell peptides to the public. Omega Peptides Australia is not a pharmacy and does not compound medicines. We supply the lyophilised research compound, with batch COAs, strictly for in-vitro laboratory use.

How do you reconstitute BPC-157?
Use bacteriostatic water. Wipe the vial stopper, draw up the chosen volume of water and add it slowly down the inside wall of the vial so it runs onto the powder rather than jetting into it. Swirl gently until the solution is clear, do not shake, because agitation can fragment the peptide. Label the vial with the date and concentration, refrigerate at 2–8°C and use within 28 days. Our reconstitution calculator helps with concentration maths.

How should BPC-157 be stored?
Keep the lyophilised vial sealed, protected from light and moisture. Short-term storage at 2–8°C is fine; for long-term storage keep it at −20°C and avoid repeated freeze-thaw cycles. Once reconstituted, store the solution refrigerated at 2–8°C and use it within 28 days. Do not freeze the reconstituted solution, and allow a cold vial to reach room temperature before opening it to prevent condensation.

Where can I buy BPC-157 in Australia?
Directly from Omega Peptides Australia. Stock is held domestically, orders placed before 12pm are dispatched the same day, and every batch is COA-verified by Janoshik Analytical with certificates published in our COA library. You can browse BPC-157 alongside our full range of research peptides in Australia, including TB-500, the BPC-157 + TB-500 blend and multi-peptide blends such as KLOW and GLOW.

What does BPC-157 cost in Australia?
BPC-157 10mg is $99.99 per vial, which works out to about $10.00 per mg. The combined BPC-157 + TB-500 blend, with 5mg of each peptide in a single 10mg vial, is $119.99, and the oral capsule format (100 capsules at 500mcg) is $249.99. Bacteriostatic water for reconstitution is sold separately, and Australian pricing includes domestic dispatch without import duties or customs delays.

How do I get BPC-157 online in Australia?
Add the 10mg vial to your cart on this page, add bacteriostatic water if you need it, and complete checkout. Orders are shipped from within Australia with tracked domestic delivery and discreet, unbranded packaging. Orders placed before 12pm on a business day are dispatched the same day; later orders leave the next business day. A tracking number is emailed as soon as the parcel is scanned.

Is BPC-157 legal in Australia?
Omega Peptides Australia supplies BPC-157 strictly for lawful in-vitro laboratory research. It is not approved by the TGA for human or veterinary use and is not sold as a medicine or supplement. Purchasers are responsible for ensuring their intended use complies with all applicable laws.

What is the difference between the BPC-157 vial and BPC-157 capsules?
The 10mg vial contains lyophilised powder that is reconstituted into a solution of known concentration, which suits cell-culture assays and the injection-based animal models that dominate the tendon and muscle literature. BPC-157 capsules contain a pre-measured 500mcg per capsule (100 per bottle) and are used in oral-administration and gastrointestinal research designs, taking advantage of the peptide's stability in gastric juice. Both are COA-verified.

Is BPC-157 available in Australia?
Yes, as a research-grade lyophilised compound from domestic research suppliers. It is not a registered medicine and is not sold through pharmacies. Omega Peptides Australia holds BPC-157 10mg vials and capsules in Australian stock with same-day dispatch before 12pm.

Can you get BPC-157 in Australia?
Yes, from an Australian research peptide supplier that holds domestic stock and publishes a certificate of analysis per batch. Omega Peptides Australia dispatches BPC-157 from within Australia on tracked delivery, with the batch COA available before purchase.

⚠ For in-vitro research and laboratory use only. Not for human or veterinary use.